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disease in Soweto;(1,3) reflecting high levels of hypertension in 
urban communities in sub-Saharan Africa as a whole.(4) Secondary 
prevention programmes designed to not only detect those with 
established and often disabling forms of heart disease and other 
forms of CVD (including ischaemic and non-ischaemic forms of 
stroke),(5) but prevent disease progression and a premature 
death, are an obvious priority.
Fortunately, additional data from primary care clinics in Soweto, 
suggest there is still time to limit the number of typically advanced 
presentations of CVD because many cases of hypertension 
(representing 1 in 3 primary care contacts) have yet to present 
with end organ damage.(6) Alternatively, the general lack of blood 
pressure (BP) control despite pharmacological treatment, over-
whelming burden of communicable diseases and other health issues 
(compared to only 3 in 100 primary care cases with an advanced 
form of CVD) and poor resources, are a stark reminder of the 
challenging environment confronting anyone wishing to improve 
health outcomes in this setting.(7)    
IntroductIon                                                              
There is increasing recognition that the diverse people of sub-
Saharan Africa face a number of paradoxical challenges arising from 
economic development and urbanisation. Whist these promise a 
reduction in the diseases of poverty (predominantly malnutrition 
and infectious disease) they will undoubtedly come at a price with 
a parallel rise in non-communicable forms of cardiovascular disease 
(CVD). A recent report from the Heart of Soweto Study, suggested 
that the urban, predominantly African community of more than 
1 million people, stands at the crossroads between traditional/
communicable forms of heart disease (including rheumatic heart 
disease (RHD) and the dilated cardiomyopathies)(1) and non-
communicable forms of heart disease linked to epidemiological 
transition.(2) The most profound finding of this study is that women 
predominate and that de novo cases of often-advanced forms of 
heart disease from both sexes are far younger than that seen in 
high-income countries. Although cases of coronary artery disease 
(CAD) are on the rise, it is hypertensive heart failure (HF) that 
represent the most common form of non-communicable heart 
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the diverse people of sub-saharan Africa face a number of 
paradoxical challenges arising from economic development 
and urbanisation, including an increasing prevalence of non-
communicable forms of heart disease. Prevention program-
mes designed not only to detect those with established and 
often disabling forms of heart disease, but prevent disease 
progression and a premature death, are an obvious priority 
in this setting.  this review article reflects on the barriers and 
challenges to effective primary and secondary prevention of 
heart disease in sub-saharan Africa by (a) examining what 
residual issues challenge effective prevention in high-income 
countries?  (b) what are the key ingredients to an integrated 
programme of primary and secondary prevention across the 
lifespan (from the population to individual)? and (c) con-
sidering the first two points, what are the barriers and chal-
lenges in sub-saharan Africa to implementing cost-effective 
primary and secondary prevention using a systematic 



















This review article reflects on the barriers and challenges to effective 
primary and secondary prevention of heart disease in sub-Saharan 
Africa by (a) examining what residual issues challenge effective 
prevention in high-income countries?; (b) what are the key 
ingredients to an integrated programme of primary and secondary 
prevention across the life-span (from the population to individual)? 
and; (c) considering the first two points, what are the barriers and 
challenges in sub-Saharan Africa to implementing cost-effective 
primary and secondary prevention using a systematic approach to 
“who, what and how”?
Lessons from hIgh-Income countrIes:           
from hyPertensIon to heArt fAILure
In establishing draft guidelines for the (updated) management of 
hypertension in the United Kingdom,(8) NICE has recently attempted 
to tackle a number of critical issues that have weakened past 
attempts to optimally control blood pressure as part of effective 
primary and secondary prevention of CVD. Given that these 
guidelines are directed towards one of the “core” risk factors for 
CVD prevention originally identified by the Framingham Study(9) 
and the subject of years of global research efforts and investment 
in developing accurate and reliable monitors,(10) pharmacological 
therapies,(11) identifying key indicators of organ damage,(12) 
delineating the pattern and contribution of hypertension from a 
regional(13) to tertiary care perspective,(3) determining key thresh-
olds for long-term risk(14) and perhaps harm from anti-hypertension 
treatment(15) and, most recently, innovative ways to treat resistant 
forms of hypertension,(16) it is perhaps surprising that NICE has 
decided to revisit a number of key areas. Firstly, the very founda-
tion for diagnosing hypertension is being challenged with measure-
ments taken in the clinic/office setting regarded as unreliable due 
to the phenomenon of “white coat hypertension”. Instead, the 
draft guidelines propose the use of 24-hour ambulatory BP 
monitoring to definitively establish the presence of hypertension 
in affected individuals.(8) Secondly, consistent with recent Australian 
guidelines,(17) NICE propose to permanently abolish the tradi- 
tional one dimensional approach to establishing BP targets and 
treatment thresholds (i.e. using the simple BP threshold of 140/90 
mmHg to detect and potentially treat hypertension) to incorporate 
absolute risk profiling for those without established forms of 
CVD and lower thresholds for those with CVD (or evidence of 
end-organ damage). Lastly, instead of advocating first-line diuretic 
therapy the use of calcium channel antagonists or angiotensin con-
verting enzyme inhibitors (depending on the age of the affected 
individual) with preference given to cheaper, generic brands.(8) 
Whilst there are recommendations to simplify treatment (to maxi-
mise adherence) and apply combination therapies for those not 
responding to mono-therapy, surprisingly, there is little considera-
tion of the difficulties in applying complex guidelines for even a 
seemingly simple condition such as hypertension.(18) Coordinating 
management of hypertension through primary healthcare initiatives 
represents an important, but often, under-estimated component of 
wider BP control.(19) 
At the other end of the spectrum (i.e. from treating hypertension 
as a primary risk factor), in the past, there have been similar issues 
in determining optimal ways to detect and manage the syndrome 
of chronic HF (CHF) in the ageing populations of high-income 
countries. In contrast to attempts to raise the threshold for 
diagnosing hypertension (effectively reducing the number of 
treated cases), the evolving definition of CHF has effectively 
ensured more cases are diagnosed (with both preserved and 
impaired systolic function) and actively treated to prevent disease 
progression; despite the lack of specific treatments for non-
ischaemic forms of the syndrome.(20) A key role for CHF manage-
ment programmes that coordinate the detection and management 
of CHF has emerged, underpinned by meta-analyses that have 
demonstrated their secondary prevention benefits in respect to 
reduced hospitalisation and prolong survival.(21) However, their 
application remains problematic with imperfect application of the 
evidence in real-life,(22) new studies questioning the modern-day 
impact of face-to-face programmes of care(23) (despite strong 
historical evidence) and conflicting evidence from studies of remote 
monitoring techniques that aim to automate CHF management 
via more sophisticated (and more costly) technology.(24)        
There is a cautionary tale, therefore, from the detection and 
management of one of the simplest of risk factors (hypertension) 
to the most complex of syndromes (CHF) in high-income countries 
with much to be resolved in terms of even simple concepts of 
defining risk and when to treat for optimal primary and secondary 
prevention. Overall, there is much to be learned from the rest of 
the world, both positive and negative. If anything, a strong filter 
needs to be applied by local experts who understand the dynamics 
of heart disease in sub-Saharan Africa and are determined to strip 
away much of the commercialism and complexity that character-
ises healthcare in the rest of the world on the “fundamentals” of 
prevention that yield the greatest impact at the lowest cost.
IntegrAted PrImAry And secondAry                   
PreventIon
Figure 1 represents an integrated and holistic model of primary and 
secondary prevention of heart disease. It recognises the different 
stages of heart health across the life span and the factors, from the 
individual to the whole population, that influence this and need 
to be positively influenced to promote wellness and longevity. 
Although it incorporates some of the unique challenges inherent to 
sub-Saharan African and other low- to middle-income regions of 
the world, it still reflects the same challenges for integrated pre-
vention faced by any healthcare system around the globe. Pre-
vention should be regarded as a series of battles. If we cannot 
prevent the development of heart disease at an early age (e.g. by 
promoting maternal health), we can at least detect and pro-actively 
treat it to prevent its progression into a deadly and disabling form. 
If we cannot prevent the development of chronic heart disease 
(e.g. by controlling blood pressure in those with hypertension and/
or pro-actively treating those with acute rheumatic fever), we can 
at least ensure the affected individuals lives as long as possible with 
optimal quality of life.
The components of effective prevention (as represented in the 
figure) whilst fairly incontrovertible, are only effective when they 
can be applied consistently and efficiently with the right tools (this 
includes pharmacological treatments) and resources (including key 
healthcare professionals). As explored in the next section, sub-
Saharan Africa has unique barriers and challenges that need to be 
addressed in order to prevent its diverse peoples not only suffering 
from the diseases of poverty but prevent them entering a transi-
tional phase where those fortunate enough to survive the former 
are at high risk from developing (and dying prematurely from) non-
communicable forms of heart disease.(7)
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population strategies
 ■ Socio-economic development
 ■ Reduce burden of infection & malnutrition
 ■ Enhance maternal & childhood health services
 ■ School-based health surveillance & health programmes
 ■ Tobacco control, salt reduction & healthy food supply
 ■ Primary health surveillance & treatment services
 ■ Whole population treatment programmes - ”pollypill”
 ■ Secondary prevention/heart disease care services
individual strategies
 ■ Surgery for congenital abnormalities
 ■ Early detection & prophylaxis for potential RHD
 ■ Family-based interventions to reduce risk
 ■ Individual health coaching & training
 ■ CV risk profiling & treat to ideal targets
 ■ CV screening & treatment of at risk individuals
 ■ Secondary prevention programmes for tertiary cases



















Unfortunately, the political will and ability to fund pro-active 
programmes of this type are many and varied in the region. A 
consistent approach, perhaps funded by international agencies, 
across the region is undoubtedly required.
Specific recipients
From both a primary and secondary prevention perspective, there 
are aspects around the pattern of risk and, indeed, disease in the 
region that require further elucidation before a robust evidence 
base for individualised prevention (as opposed to the population-
based strategies described above) can be reliably applied. Key 
issues include:
 ■ Individual risk factors (including elevated BP and dyslipidaemia) 
as targets for prevention are largely derived from North 
American and European populations with completely different 
natural histories and consequences.
 ■ There is no reliable absolute risk score for the African 
population to describe the impact of combined risk factors and 
their longer-term prognostic importance.
 ■ The development of cheap and reliable tools (e.g. automated 
BP monitors and portable imaging devices)(29) is restricted by a 
lack of public funding and market forces to encourage private 
industry to develop and market such devices. 
 ■ National/international funding for surveillance programmes to 
detect non-communicable forms of disease are far inferior to 
those devoted to those with a communicable component.(30)
 ■ The confounding impact of a high underlying burden of 
communicable disease states (i.e. tuberculosis, HIV/AIDS and 
RHD) are yet to be fully elucidated in respect to the “classical” 
risk factors.
The result of these and other key barriers is a fragmented picture 
of risk and established heart disease in the region with many 
unknowns as to specific priorities given the lack of data to deter-
mine who would benefit most from individualised prevention 
programmes.
bArrIers And chALLenges for sub-                      
sAhArAn AfrIcA
It is beyond this broad review of primary and secondary pre- 
vention in sub-Saharan Africa to provide a detailed blueprint for 
effective prevention in the region. Whilst contemplating the 
challenges of applying any health intervention in a resource poor 
environment(7) it is vital that a systematic approach to articulate 
what is trying to be achieved (in this cost-effective case primary and 
secondary prevention) and how that might be achieved is applied. 
It is within this context that the American Heart Association 
Disease Management Taxonomy Writing Group’s scientific state-
ment designed to standardise the application of disease manage-
ment are worth considering.(25) Adapting the eight key domains 
identified in this statement, it is possible to identify some of the 
barriers and challenges to effective prevention in the region.
target population
The enormous geo-political and socio-cultural diversity of sub-
Saharan Africa mandates a region (or community) specific approach 
to identifying those most at risk of developing heart disease and 
therefore the target for primary prevention programmes. Much 
like a multi-national corporation developing a global strategy for 
developing an overall market for a particular product (e.g. a 
carbonated drink) and then varying its branding, supply and cost 
according to local factors to sustain interest and consumption, 
prevention does not represent a “one size fits all” strategy. At 
the very least it would appear that broad strategies for restricting 
the use of tobacco (through the combination of taxes and ban- 
ning smoking in public places), lowering salt intake (through regu- 
lation of food manufacturing) and promoting healthier diets with 
less saturated fat and sugars (via food regulation and pricing 
policies), promoting exercising and educating the public (particu-
larly through school programmes) are easy to articulate but often 
hard to apply.(26,27) However, when properly applied they have 
the potential to reach the maximal number of people from a 
primary prevention perspective. Clearly, other programmes to 
facilitate early detection and management of non-fatal congenital 
heart disease in newborns, long-term prophylaxis for children at 
risk of rheumatic heart disease and the proactive management 
of individuals being treated with anti-retroviral therapy for HIV/
AIDS are high priorities for the region.(28)
intervention component
As indicated earlier, any “blind” application of therapeutic strate-
gies applied in high-income countries in completely different 
ethnic groups with completely different disease trajectories (par-
ticularly considering the historical absence of communicable 
disease) is fraught with danger. For example, a polypill containing 
a statin to reduce cholesterol levels and/or aspirin to prevent 
thrombotic events secondary to atherosclerosis(31) may well prove 
to be extremely harmful in populations in whom cholesterol levels 
remain extremely low, coronary artery disease and other form of 
atherosclerosis remain rare, but rates of haemorrhagic stroke 
remain high.(5) Similarly, the needs of hypertensive individuals of 
African descent with a greater potential for salt sensitivity,(3) 
requires a markedly different approach to that applied in Europe. 
As indicated earlier, the evidence-base for primary and secondary 
prevention strategies are largely non-African in origin. Major com-
mercial investment to undertake the primary research to validate 
established treatments is unlikely to occur until a critical mass of 
consumer and government support for therapeutic products 
accompanies economic development. In the meantime, there is 
urgent need to promote access to and use of cheap generic drugs 
that have the most favourable benefit-to-risk profile in the sub-
Saharan context. Similarly, the large disparity between non-com-
mercial funding of strategies (predominantly international agencies 
such as the World Health Organisation) for communicable versus 
non-communicable disease states in sub-Saharan Africa (and other 
vulnerable regions) needs to be urgently addressed.(30)
delivery personnel
There is little doubt that sub-Saharan Africa, as a whole, suffers a 
critical shortage of health professionals (from nurses to cardiolo-
gists) with the requisite experience and training to apply rudiment-
ary to advanced primary and secondary prevention programmes; 
from simple BP measurements to advanced investigations and 
management of the cardiomyopathies (often requiring careful 
delineation of underlying cause and impact on cardiac structure and 
function). In the longer-term, there is critical need to train and 
support a new generation of nurses, doctors and key allied health 
professionals (including dieticians, imaging technicians and rehabi-
litation experts) who can provide a network of expertise across 
integrated primary and secondary care services.
In the short-term, there is a clear need for the application of 
innovative technology (such as simple and reliable BP monitors)(10) 
that permits lay individuals to provide accurate risk assessments 
from a primary prevention perspective and with sufficient training 
to provide effective healthcare messages (see below) and/or treat-
ments (e.g. a polypill).(31) At the same time, school teachers could 
be used to promote heart healthy messages – particularly if 
supported by surveillance programmes and dedicated education 
programmes. Community workers who are trained to undertake 
simple health assessments and deliver key health messages could 
well supplement the current network of primary and tertiary 
healthcare services throughout the region.
Method of communication
Health literacy is a growing discipline in the context of primary 
and secondary prevention as awareness of the “knowledge gap” 
between the delivery of key messages by health professionals and 
the consequent understanding by targeted individuals/communities 
is appreciated. Certainly, any prevention programmes needs to 
employ a multi-modal approach to delivering key messages. In high-
income countries, with high literacy levels and use of information 
technology, there is a natural (if not proven) progression towards 
more sophisticated prevention programmes. In sub-Saharan Africa, 
it is much more likely that a combination of oral (i.e. one-to-one 
counselling and or small group lectures), visual (i.e. pictorials) and 
written (simple brochures and posters) materials will prove to be 
most effective in promoting important preventative messages.
intensity and complexity
As indicated by Figure 1, an integrated prevention programme will 
encompass relatively simple health messages and programmes to 
adjust the overall risk and potential disease profile of a whole 
population (e.g. raising awareness of the consequences of tobacco 
use) to individualised secondary disease prevention/management. 
Clearly, the latter represents a more costly component with its 
requirements for increasingly sophisticated healthcare services and 
trained personnel. Cost-effective secondary prevention remains an 
elusive goal in high-income countries. Ultimately, it is likely to be 
achieved when the right combination of risk delineation (for disease 
progression) is coupled with a “titrated” approach to intervention; 
from routine follow-up to more aggressive forms of management 
(including pharmacotherapy and coaching to ideal targets on an 
individual basis).(32)





















Given the lack of integrated primary and tertiary healthcare 
services, it appears clear (at least until such an investment in 
dedicated services and personnel is made) that both primary and 
secondary prevention in the region should be focussed in the 
community and public institutions. The family unit and home, for 
example, may well prove to be the most powerful environment 
for triggering changes in the pattern of food intake, exercise and 
reducing exposure to extraneous risk factors. As indicated above, 
this could be facilitated by trained community workers who are 
able to work with the limited number of primary and tertiary 
healthcare services to reach a wider population. 
Clinical outcomes
Regardless of delivery, it is clear that any primary prevention 
programme will aim to reduce the overall risk profile of a particular 
individual/community/region and demonstrate reduced progres-
sion to preventable forms of CVD. Similarly, the secondary 
prevention programmes aim to prevent disability, hospital use and 
premature death. However, in order to properly assess any 
programme, it is essential that a number of parameters are docu-
mented and the potential of prevention truly understood. These 
include understanding:
 ■ The major risk factors (i.e. those with the highest population 
attributable risk) that if addressed, will lead to the greatest 
reduction in primary and secondary events.
 ■ The underlying incidence and prevalence of these risk factors.
 ■ The underlying incidence and prevalence of the major forms of 
heart disease and other forms of CVD within the overall 
(target) population.
 ■ Rates of hospitalisation attributable to the major forms of CVD.
 ■ Case-fatality rates attributable to the major forms of CVD 
within the whole population and within high-risk groups.
Unfortunately, there is a paucity of such data in sub-Saharan Africa 
and systematically acquiring such data to map-out the maximum 
potential benefits of prevention, particularly within a fluid socio-
economic environment, is of paramount importance. 
concLusIons                                                                  
The challenges and barriers to effective primary and secondary 
prevention of heart disease in sub-Saharan Africa are enormous 
but not insurmountable. Unlike high-income countries that entered 
an epidemic of acute and chronic forms of heart disease with 
minimal warning and preparation and are still struggling to deliver 
cost-effective prevention, the diverse populations of sub-Saharan 
Africa still have time to change their current trajectory towards an 
epidemic of non-communicable forms of heart disease. Never-
theless, early signs are not encouraging. It appears a deadly mix of 
communicable forms of heart disease combining with non-
communicable forms of disease affecting relatively young individuals 
(predominantly women) is becoming more evident in urban 
communities such as Soweto where socio-economic development 
continues to gather pace.(1) With limited resources at present, it is 
clear that wise investments in integrated primary and tertiary 
healthcare services and trained healthcare professionals with an 
understanding of the evolving threat of non-communicable disease, 
will result in healthier more productive communities in the future. 
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